1. Cell Cycle/DNA Damage Epigenetics Apoptosis
  2. HDAC Apoptosis
  3. Romidepsin

Romidepsin  (Synonyms: FK 228; FR 901228; NSC 630176)

Cat. No.: HY-15149 Purity: 99.85%
COA Handling Instructions

Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis.

For research use only. We do not sell to patients.

Romidepsin Chemical Structure

Romidepsin Chemical Structure

CAS No. : 128517-07-7

Size Price Stock Quantity
1 mg USD 132 In-stock
5 mg USD 300 In-stock
10 mg USD 540 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 45 publication(s) in Google Scholar

Top Publications Citing Use of Products

42 Publications Citing Use of MCE Romidepsin

WB
Cell Viability Assay

    Romidepsin purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2023 Mar 13;41(3):602-619.e11.  [Abstract]

    The triple combination of E + R + iC significantly decreases tumor volume compared with double combinations, in mice. E: enzalutamide (30 mg/kg; p.o.; single daily for 10 days); R: Romidepsin (0.3 mg/kg; i.p.; single daily for 10 days); iC: CXCR2 inhibitor.

    Romidepsin purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2018 Sep 13;14(9):e1007267.   [Abstract]

    Immunoblot analysis for vIL-6, ORF45, or actin is performed on lysates from BCBL-1 cells treated with NaB+TPA, Romidepsin or LBH589.

    Romidepsin purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2017 May 12;653:12-18.  [Abstract]

    Romidepsin increases histone acetylation in SH-SY5Y neuroblastoma cells. Western blots of pAcH3 and β-actin levels in SH-SY5Y cells cultured for 24 h with 0-40 nM of Romidepsin. 20 nM and 40 nM Romidepsin significantly increase the levels of pAcH3 relative to control, which is measured by densitometric quantification of pAcH3 protein levels relative to β-actin loading control.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively[1]. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis[2].

    IC50 & Target[1]

    HDAC1

    36 nM (IC50)

    HDAC2

    47 nM (IC50)

    HDAC4

    510 nM (IC50)

    HDAC6

    14000 nM (IC50)

    In Vitro

    Romidepsin (0-72 hours; 0-80 nM) inhibits proliferation of HCC cells in dose-dependent manner[2].
    Romidepsin (0-48 hours; 0-60 nM) leads to a time- and dose-dependent induction of cell cycle arrest in the G2/M phase in HCC cells[2].
    Romidepsin (0-48 hours; 0-60 nM) promotesapoptosis in HCC cells, increases c-caspase-3, c-caspase-9, and c-PARP protein expression[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[2]

    Cell Line: HCC cells
    Concentration: 0 nM; 10 nM; 20 nM; 30 nM; 40 nM; 50 nM; 60 nM; 70 nM; 80 nM
    Incubation Time: 0 hours; 12 hours; 24 hours; 48 hours; 72 hours
    Result: Inhibited HCC cells proliferation.

    Cell Cycle Analysis[2]

    Cell Line: HCC cells
    Concentration: 0 nM; 15 nM; 30 nM; 60 nM
    Incubation Time: 12 hours;24 hours; 48 hours
    Result: Caused a G2/M arrest.

    Western Blot Analysis[2]

    Cell Line: HCC cells
    Concentration: 0 nM; 15 nM; 30 nM; 60 nM
    Incubation Time: 12 hours;24 hours; 48 hours
    Result: Increaesd c-caspase-3, c-caspase-9, and c-PARP expression in HCC cells.
    In Vivo

    Romidepsin (intraperitoneal injection; 0.5 and 1 mg/kg; every 3 day; 21 days) inhibited the tumor growth, reveals a higher expression of p-cdc25C, ki67, c-caspase-3 and c-PARP, and a lower expression of Ki-67 in Romidepsin treated tumors [2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nude mice with Huh7 cells[2]
    Dosage: 0.5 and 1 mg/kg
    Administration: Intraperitoneal injection; 0.5 and 1 mg/kg; every 3 day; 21 days
    Result: Suppressed tumor growth in mouse xenograft models.
    Clinical Trial
    Molecular Weight

    540.70

    Formula

    C24H36N4O6S2

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C/C=C(NC([C@@H](CSSCC/C=C/[C@@H](O1)CC2=O)NC([C@@H](C(C)C)N2)=O)=O)/C(N[C@@H](C(C)C)C1=O)=O

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years

    *The compound is unstable in solutions, freshly prepared is recommended.

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (184.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.8495 mL 9.2473 mL 18.4945 mL
    5 mM 0.3699 mL 1.8495 mL 3.6989 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.08 mg/mL (3.85 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *The compound is unstable in solutions, freshly prepared is recommended.

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.98%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.8495 mL 9.2473 mL 18.4945 mL 46.2364 mL
    5 mM 0.3699 mL 1.8495 mL 3.6989 mL 9.2473 mL
    10 mM 0.1849 mL 0.9247 mL 1.8495 mL 4.6236 mL
    15 mM 0.1233 mL 0.6165 mL 1.2330 mL 3.0824 mL
    20 mM 0.0925 mL 0.4624 mL 0.9247 mL 2.3118 mL
    25 mM 0.0740 mL 0.3699 mL 0.7398 mL 1.8495 mL
    30 mM 0.0616 mL 0.3082 mL 0.6165 mL 1.5412 mL
    40 mM 0.0462 mL 0.2312 mL 0.4624 mL 1.1559 mL
    50 mM 0.0370 mL 0.1849 mL 0.3699 mL 0.9247 mL
    60 mM 0.0308 mL 0.1541 mL 0.3082 mL 0.7706 mL
    80 mM 0.0231 mL 0.1156 mL 0.2312 mL 0.5780 mL
    100 mM 0.0185 mL 0.0925 mL 0.1849 mL 0.4624 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Romidepsin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Romidepsin
    Cat. No.:
    HY-15149
    Quantity:
    MCE Japan Authorized Agent: